The Preterm Prebiotic Study

[X] Prospectively registered Submission date Recruitment status 20/08/2005 No longer recruiting [] Protocol [] Statistical analysis plan Registration date Overall study status 12/09/2005 Completed [X] Results [] Individual participant data Last Edited Condition category 01/02/2013 **Neonatal Diseases**

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)Scientific

Contact name

Prof Neena Modi

Contact details

Imperial College London Chelsea & Westminster Hospital 369 Fulham Road London United Kingdom SW10 9NH

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers NRG / II DbCoRPMc / PT EL 01

Study information

Scientific Title

Study objectives

Supplementation of a preterm formula with 0.8 g galacto-oligosaccharides (GOS)/fructo-oligosacharides (FOS) mixture per dl (ratio: 9:1) will result in an improvement in enteral tolerance.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Neonatal nutritional supplementation

Interventions

Infants randomised to one of two groups receiving either Nutriprem A or B, one without and one with 0.8 g GOS/FOS oligosaccharides /dl, to make up any shortfall in their own mothers milk or as sole diet if maternal milk is unavailable.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Galacto-oligosaccharides (GOS)/fructo-oligosacharides (FOS)

Primary outcome measure

1. Number of days from birth to reach a total (sole formula or formula with breast milk) daily enteral intake of 150 ml/kg

2. Number of days between birth and 28 days that a total (sole formula or formula with breast milk) daily enteral intake of at least 150 ml/kg is tolerated

Secondary outcome measures

- 1. Gain in weight, length and head circumference
- 2. Faecal flora
- 3. Faecal calprotectin
- 4. Faecal characteristics
- 5. Gastrointestinal tolerance
- 6. Fluid balance
- 7. Necrotising enterocolitis
- 8. Bloodstream infection

Overall study start date

01/10/2005

Completion date

30/06/2007

Eligibility

Key inclusion criteria

Preterm infants, appropriately grown for gestational age, with a gestational age \leq 32 + 6 weeks (days), whose mothers agree to the use of formula if they are unable to or do not wish to breast feed or are not able to provide sufficient breast milk

Participant type(s)

Patient

Age group

Neonate

Sex

Both

Target number of participants

160

Key exclusion criteria

- 1. More than 72 hours exclusive parenteral nutrition
- 2. Immediately life-threatening congenital abnormality
- 3. Any condition requiring major surgery

Date of first enrolment

01/10/2005

Date of final enrolment

30/06/2007

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Imperial College London

London United Kingdom SW10 9NH

Sponsor information

Organisation

Milupa GmbH, Numico Research (Germany)

Sponsor details

Bahnstrasse 14-30 Friedrichsdorf Germany 61381

Sponsor type

Industry

ROR

https://ror.org/00aj77a24

Funder(s)

Funder type

Industry

Funder Name

Numico Research (Germany)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2010		Yes	No